Click here to read the cover story, "Biosimilars have yet to make an impact in ophthalmology"
Undoubtedly, cost can be a barrier to optimal anti-VEGF treatment in the United States and around the world.
The burden of retinal disorders is increasing. In fact, cases of age-related macular degeneration are estimated to be 196 million globally but estimated to increase to 288 million by 2040. Therefore, cost-effective biologic therapies are needed.
Biosimilars are becoming a well-established treatment option not only in retina but in other areas of medicine. They can improve (Read more...)